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Abstract
We consider a simple multi-IV model for drug concentration in the case of
poor patient compliance. The model is a stochastic one, and is thus able to
take into account an irregular drug intake schedule. Under some assump-
tions, we study features of the drug concentration relevant for practical pur-
poses such as its variability or the regularity of its cumulative probability
distribution. We consider five variants: random instants for drug intake with
either deterministic or random doses, both in continuous and discrete-time
settings, plus a model with stochastically varying elimination rate. Our com-
putations make it possible to assess in a precise way the effect of various sig-
nificant parameters such as the mean rate of intake, the elimination rate, and
the mean dose. They also quantify how much poor compliance will affect
the regimen: in that view, we provide precise comparisons with the vari-
ability of concentration in the cases of (a) a fully compliant patient and (b)
a population of fully compliant patients with lognormally distributed elimi-
nation rates. The time discretized version of our models reveal unexpected
links with measures known as infinite Bernoulli convolutions. Our findings
help in understanding the consequences of poor compliance, and may have
practical outcomes in terms of drug dosing and scheduling.
1
1 Introduction
Poor adherence to medical treatment is a problem of the utmost importance that
has critical impact on the efficacy of therapy, particularly in the case of chronic
diseases [20]. Compliance to pharmacotherapy can range from 5% to 90% [7].
Because of this, therapies tested on strictly adhering patients may reveal ineffec-
tive in ambulatory settings: as shown in [9], the drug concentration time evolution
is heavily influenced by the random drug input generated by patients with poor
adherence behaviour.
In the seminal work [9], the authors attacked the problem of mathematically
modelling poor compliance using a probabilistic frame. They considered general
distributions for the random instants of drug intake and studied the mean and vari-
ance of the concentration conditioned on the time elapsed since the last intake.
Our work is similar in spirit. The present article is the first in a series of three
where we will consider models of increasing generality and complexity. More
precisely, we investigate below the probability distribution of drug concentration
in the context of multiple-IV dosing and poor compliance: patients takes their
drugs at random times, with possibly random doses. In this work, we use the sim-
plest possible law to model the random times of drug intake, i.e. a homogeneous
Poisson distribution. In other words, the moments of drug intake are supposed to
follow a Poisson process. This assumption allows one to perform explicit compu-
tations using the well-developed machinery on Poisson processes, and to obtain
precise results describing various aspects of the distribution of the concentration
that are important for assessing the efficacy of the regimen. Indeed, we focus on
two aspects of practical relevance: the variability of the concentration and the reg-
ularity of its probability distribution. It is intuitively obvious that poor compliance
will increase the variability of the concentration around its mean as compared to
the full compliance case. In addition, it may also have an impact on the regularity
of the distribution of the concentration, resulting in a high probability of having
too small a concentration of drugs. Our results quantify this in a precise way,
showing the exact role played by each parameter of the process.
An even more radical situation occurs if, instead of considering a continuous
time model, one investigates a time-discretized version, where doses may be taken
only at discrete times: in this setting, the problem at hand reveals unexpected links
with mathematical objects that have been studied in the literature for over seventy
years under the name of infinite Bernoulli convolutions. Again, depending on
some parameters, the discretized concentration may exhibit an extremely irregular
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behaviour. In effect, this means that the probability of observing a concentration
C depends in a very non-smooth way on the precise value of C. This is obviously
an undesirable feature which may have strongly negative consequences.
We compare the variability induced by non compliance to the one induced by a
distribution of elimination rates in a population. This helps putting in perspective
the negative impacts of poor compliance.
We also consider the case where not only the intake times and doses are ran-
dom, but also is the elimination rate across time. While this is not strictly related
to poor compliance, such an analysis allows one to draw interesting conclusions,
by comparing the effects of poor compliance to the ones due to a time varying
elimination rate.
We do not address in this work the problem of estimating the parameters of
the various models, in particular the law of the random intake times and doses. A
recent article dealing with this issue is [2].
We end this introduction with a word on our modelling choices: clearly, the
use of the multiple-IV model as well as the one of the homogeneous Poisson law
for the random instants of intake are somewhat restrictive. Indeed, the problem
of irregular drug-intake intervals is more likely to happen in the frame of oral
administration than in the IV case. Likewise, the irregular schedule ought to be
too complex in general to be described satisfactorily by a homogeneous Poisson
law. However, we believe that our choice of describing results in the multiple-IV
model / Poisson law as a first step are justified by the following facts:
• The essential theoretical ideas are already present in this simplified setting,
allowing one to grasp the main mechanisms through which poor compliance
impacts concentration.
• The mathematical apparatus, although still reasonably simple, draws on a
few advanced concepts and requires sometimes lengthy computations. They
serve as a intermediate step for the more complex analysis needed in the oral
case / general schedule.
• The results presented below already help understanding the practical conse-
quences of poor compliance, and may be used as rough guidelines for drug
dosing and scheduling.
We will go beyond these limitations in two sequels of this work : in the first
one, we will study the more realistic multi-oral model, and deal with the compli-
cations brought by the first-order kinetics, which are essentially technical. The
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second one will consider a more powerful mathematical frame, known as Piece-
wise Deterministic Markov Model, that will allow us to deal with general drug
intake schedules, going beyond the homogeneous Poisson case.
The remaining of this work is organized as follows: for the reader’s conve-
nience, we present an overview of our main findings pertaining to the various
models and their practical implications in the next section. A reader not inter-
ested in the mathematical details may concentrate on this section to get a quick
summary of our work, and refer if needed to the details in the following sections.
In Section 3, we set up the basic continuous time model for deterministic dose
random time drug intake and study its variability (Subsection 3.1) and regular-
ity (Subsection 3.2). In Section 4, we analyse the random doses version of this
model. As before, we study its variability (Subsection 4.1) and regularity (Sub-
section 4.2). We present the discrete-time version of this model in section 5. We
derive the discrete time concentration in Subsection 5.1 and study its variability
in Subsection 5.2. In Subsection 5.3, we show that the discrete time model tends
to the continuous time one when the discretization step tends to 0. Subsection 5.4
describes the complex regularity behaviour of the cumulative probability distribu-
tion of the concentration in the discrete time model. Section 6 parallels this for the
discrete time random dose case. Finally, Section 7 follows the same pattern in the
case of discrete time, random dose, and random elimination rate. The appendix in
Section 8 contains the proofs of some of the more technical mathematical results.
2 Overview: pharmokinetic implications of non com-
pliance
For convenience, we present in this section an overview of the random models we
consider to account for non-compliance, as well as their practical pharmokinetic
consequences. We concentrate on two aspects that are of direct relevance for as-
sessing the impact of non-compliance: variability and regularity of concentration.
Variability characterizes the probability that the random concentration becomes
”large” or ”small”, as compared to its expected values. We typically measure
variability by the variance of the random concentration, but consider other fea-
tures as well. Regularity indicates whether the concentration varies smoothly or
not. More precisely, the concentrations encountered in our models may be either:
(a) regular, which heuristically means that the probabilities of observing concen-
trations C1 and C2 are similar if C1 and C2 are close ; (b) singular at 0, indicating
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that observing a vanishing concentration has a very large probability ; (c) ev-
erywhere singular, which means that certain values of concentration have a high
probability to occur, while others, which may be almost the same, will happen
rarely. In other words, concentration in this case may vary wildly between pa-
tients. This is obviously an undesirable feature, as, for instance, it makes it more
difficult to characterize a mean behaviour. Another practical negative implication
of a singular distribution is that such a distribution will be difficult to approximate
numerically. Indeed, it is a well-known fact in non-parametric statistics (see e.g.
[19]) that the convergence rate of usual estimators for probability distributions
(such as histograms or kernel estimators) worsens when the target distribution is
singular.
In summary, variability of the concentration characterizes how far the concen-
tration typically departs from its expected one, while regularity of the concentra-
tion refers to the way it varies, i.e. smoothly or in an abrupt way.
We study these two features in five variants of non compliance: (1) a continu-
ous time model where only the time of intakes are random, (2) the same model but
where the doses are also allowed to be random, (3) a discrete time model (meaning
that drug intake may only occur at some specific, regularly spaced, time instants)
with random time intakes, (4) the same model where the doses are also allowed
to be random, (5) model (4) where we also allow the elimination rate to vary ran-
domly in time. Heuristically, the continuous time models correspond to situations
where the treatment must be taken “in the morning”, or “in the evening”, while
the discrete cases correspond to situations where the treatment must be taken at
fixed times. These models are explained in full details respectively in Sections 3,
4, 5, 6 and 7. Moreover, we compare the variabilities in the models above with the
ones in the cases of (a) full compliance of a single patient and (b) full compliance
in a population where we take into account variability due to differing elimination
rates or clearances between individuals. This allows us to highlight “equivalent
scenarios” where, for instance, we find the parameters of a non-compliant patient
that will yield the same variance in concentration as in a whole population with
given distribution of elimination rates, or, which is the same, of a single individual
whose elimination rate is unknown and is modelled as a random variable.
Before we present the non compliant models in Subsections 2.3, 2.4, 2.5, 2.6
and 2.7, we briefly analyse the variability in the fully compliant models for a single
patient (Subsection 2.1) and a population with lognormally distributed elimination
rates or clearances (Subsection 2.2).
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2.1 Purely deterministic model (full compliance)
As explained in the introduction, for simplicity and because it permits to convey
the essential features of random non-compliance, we will only consider in this
work (as is done in the first part of [9]) the case of random multidose intravenous
(IV) administration. We deal with the simple one-compartment pharmacokinetic
model with first-order elimination process of coefficient k (the elimination rate),
and apparent volume of distribution Vd. An analysis in the frame of a multiple
oral model will be presented elsewhere.
We thus assume that a patient takes a fixed dose D at regularly spaced times
t0, t1, . . . , tN , . . ., with ti = iλ , that is, the patient takes drugs every
1
λ
units of
time for some positive λ. These doses translate into immediate (i.e. at each time
ti) increases of the concentration by the value DVd . After that, the effect of the
dose taken at Ti on the overall concentration decreases exponentially fast, with
exponential speed k. Formally, this means that, at time t, the drug concentration
reads:
Cd(t) =
D
Vd
N(t)∑
i=0
exp(−k(t− ti)),
where t0, t1, . . . , tN(t) denote the instants of drug intake up to time t. The concen-
tration may also be expressed as follows:
Cd(t) =
D
Vd
∞∑
i=0
exp(−k(t− ti))1 (t > ti). (1)
We will wish to compare the values of the variances in various stochastic mod-
els below to the one in the case of full compliance. Of course, in the frame of full
compliance, there is no randomness involved, and one cannot define proper mean
and variance. However, since the concentration varies in time, it makes sense to
average it over all values of t, and define the variance correspondingly. In other
words, we denote:
Ed = lim
T→∞
1
T
∫ T
0
Cd(t)dt,
V ard = lim
T→∞
1
T
∫ T
0
(Cd(t)− Ed)2 dt
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for the mean and variance with respect to time of Cd(t). Note that Ed is closely
related to the commonly measured pharmacokinetic metric AUC. As for V ard, it
represents the time-averaged squared deviation from the long-term average, and
quantifies the variability within a cycle in the steady state. In that sense it is anal-
ogous to (but different from) the “Peak trough fluctuation” parameter considered
in the PK literature. Simple computations lead to:
Ed = µ
D
Vd
, (2)
V ard =
µ
2
(
D
Vd
)2
e
1
µ − 2µe 1µ + 2µ+ 1
e
1
µ − 1
, (3)
where µ = λ
k
. These quantities are related to ones considered in [10].
For comparison with the random models below, we note the following facts:
• For a fixed mean equal to 1, the variance of Cd tends to infinity at speed
1
12µ2
when µ→ 0. The variance tends to 0 at speed 1
2µ
when µ→∞.
• P(|Cd − E(Cd)| > γE(Cd)) 6 112µ2γ2 for large µ (see Formula (17) in
Subsection 3.1 for a more precise expression and Figure 3 for a comparison
with a non compliant case).
These formulas quantify the obvious fact that, everything else being fixed, the
variability of the concentration is a decreasing function of the number of takes
per unit time. As we shall see, non compliance amplifies the the variability of
the concentration, and we will use formula (3) to measure the strength of this
amplification.
2.2 Full compliance with population elimination rate variabil-
ity
So far we have considered the case of a single compliant subject, whose pharma-
cokinetic parameters are perfectly known. We now investigate the case of a whole
population, among which the elimination rate k presents some amount of variabil-
ity. We assume moreover that each subject in the population is fully compliant,
and that their drug intake frequency λ is the same. This amounts to replacing k
by k0Uk in the preceding computations, where Uk is a dimensionless random vari-
ate that represents the variability among subjects. We assume that Uk follows a
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lognormal distribution with parameters1 mk = 0, σ2k. The lognormal distribution
is a common modelling assumption for positive continuous quantities, and seems
to fit well with the findings of large-scale Pop-PK studies ([6, 2]). The choice
mk = 0 ensures that the reference value k0 is the median of the distribution.
We wish to examine the impact of this variability on the long-term average
concentration Ed; recall that Ed is closely related to the PK metric AUC. Let us
first assume that other pharmacokinetic parameters such as Vd are constant across
the population, so that the variations in Ed (hence also area under curve AUC and
clearance Cl) are only due to the variations of k. In other words, we consider the
random variable Ed = Ed(k0Uk), where Uk follows a lognormal distribution, and
measure its variability.
An application of the classical formula for the moment-generating function
for the Gaussian distribution (see [11]) shows that the mean and variance of Ed
across the population are given by :
Epop(Ed) =
λ
k0
D
Vd
Epop
(
1
Uk
)
=
λ
k0
D
Vd
eσ
2
k/2, (4)
Varpop(Ed) =
λ2
k20
D2
V 2d
Varpop
(
1
Uk
)
=
λ2
k20
D2
V 2d
eσ
2
k
(
eσ
2
k − 1
)
. (5)
These results can be rewritten in terms of the reduced parameter µ0 = λ/k0 and
the coefficient of variation CVk =
√
eσ
2
k − 1 of the elimination rate:
Epop(Ed) = µ0
D
Vd
√
1 + CV2k,
Varpop(Ed) = µ
2
0
D2
V 2d
CV2k(1 + CV
2
k).
The same approach applies if one wishes to take into account in addition vari-
ability of Vd across the population: starting from the expression Ed = λk
D
Vd
, one
simultaneously replaces k by k0Uk and Vd by Vd0UV , where (Uk, UV ) is a di-
mensionless random vector. Inferring the distribution of Ed from this expression
requires the knowledge of the joint distribution of Uk and UV , or at least that of
UkUV . Joint distributions are not usually reported in Pop-PK studies, but since the
product kVd is nothing but the clearance Cl, we can see that in that case:
Cl = k0UkVd0UV = Cl0UCl
1We follow the classical convention in which the parameters m,σ2 for the lognormal distribu-
tion are respectively the mean and variance of the logarithm of the random variable.
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D = 10 mg Vd = 83 l k = 0.022 h
−1
Table 1: Numerical values of the parameters used in numerical experiments.
where Cl0 = k0Vd0 and UCl = UkUV . The random variate UCl represents the
variability of clearance, and its distribution is more frequently reported in Pop-PK
studies. If we assume again a lognormal distribution with parameters mCl = 0
and σ2Cl around the median clearance Cl0 (consistent for instance with the results
of [6]), the same computations yield:
Epop(Ed) = µ0
D
Vd
eσ
2
Cl/2, (6)
Varpop(Ed) = µ
2
0
D2
V 2d
eσ
2
Cl
(
eσ
2
Cl − 1
)
. (7)
We note in passing that lognormality of clearance reported in the literature is
compatible with joint lognormality of (k, Vd).
For consistency, we will always use in the sequel the parameters of [6] in
comparing numerically the various models. These are recalled in Table 1, and
yield an AUC equal to 5.48 mg × h/l. Note that a mean elimination rate of
0.022 h−1 corresponds to a median k0 = 0.018 h−1. As an example, with a
coefficient of variation CVk = 73% (as in [6]), which corresponds to a variance
of 0.43, and assuming that doses are taken every 1
λ
= 12 h, the values of the mean
and variance of Ed are
Epop(Ed) = 0.69 mg · l−1 ; Varpop(Ed) = 0, 25 mg2 · l−2,
where we have assumed for simplicity that Vd is constant. We have plotted on
Figure 1 eight sample evolutions of the concentration for the first 14 days using
this scenario. This figure shows that the steady state (periodic concentration) is
quickly reached, though the convergence can be a little slower for smaller realisa-
tions of k (topmost curve).
In the following sections, we go back to the case of a single subject with
perfectly known PK parameters but poorly compliant behaviour, and will compare
the variability in the various cases.
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Figure 1: Eight sample paths of the concentration in the presence of elimination
rate variability for the first 14 days.
2.3 Continuous model with random intake instants and deter-
ministic doses
In the frame of poor compliance, the time instants of drug intake are modelled
as random variables instead of being fixed. We shall denote these stochastic time
instants as (Ti)i∈N and assume that the random durations Ti − Ti−1 between two
intakes are independent and identically distributed (hereafter abbreviated “i.i.d.”)
with exponential law of parameter λ. In other words, the sequence (Ti)i∈N form a
homogeneous Poisson process, and the mean duration between two drug intakes
is equal to 1
λ
. The (stochastic) concentration at time t reads:
C(t) =
D
Vd
∞∑
i=0
exp(−k(t− Ti))1 (t > Ti). (8)
This model is illustrated on Figure 2, which displays eight sample paths of the
evolution of the concentrationC(t), simulated using the parameters given in Table
1 and λ−1 = 12 h.
We show in Section 3 that C(t) has a well defined limit when t tends to infin-
ity. We are interested in the variability and regularity properties of this steady
state, or asymptotic concentration, that is denoted C. The following formulas are
established in Section 3:
E(C) = µ
D
Vd
. (9)
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Figure 2: Eight sample paths of the concentration with Poisson distributed instants
of intakes, for the first 14 days.
Var(C) =
µ
2
(
D
Vd
)2
. (10)
In view of (2) and (3), we remark that:
• as expected, the means are the same in the deterministic and random mod-
els;
• for a fixed mean equal to 1, the variance of C is equal to 1
2µ
. It thus tends at
this speed to 0 when µ→ 0 (six times more slowly than in the deterministic
model) and to infinity when µ → ∞ (same speed as in the deterministic
model);
• P(|C−E(C)| > γE(C)) 6 1
2µγ2
for all µ. We plot on Figure 3 a comparison
between this bound and the one in the fully compliant case given by Formula
(17) (see Subsection 3.1).
• the probability that the long-term concentration exceeds a given level U
decays as 1
U2
. More precisely, P(C > U) 6 7
6U2
(
D
Vd
)2
µ
(
µ+ 1
2
)
. With
µ D
Vd
= E(C) constant, one sees that this probability decays faster for larger
values of µ.
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Figure 3: Probabilities that the concentration will significantly depart from its
mean (Formulas (16) and (17)) in the cases of full compliance (dashed) and non
compliance with random instants of intake (solid), as a function of µ. Left: γ =
0.2, right: γ = 0.5.
We see that, in a similar way as was observed in the deterministic model,
the variability of the concentration is a decreasing function of the expected num-
ber of takes per unit time: as is intuitively clear, increasing the mean frequency
of intakes while keeping constant the average quantity of administrated drug di-
minishes the negative impact of poor compliance in terms of the probability of
departing significantly from the mean concentration. However, the same value of
µ yields larger variability in the non-compliant case than in the deterministic one,
in a way quantified by the formulas above. To illustrate the differences between
the variances in the deterministic -formula (3)- and random cases -formula (10)-,
we plot on Figures 4 and 5 their evolutions as a function of µ, in two situations.
First, we let µ vary and keep the other parameters, i.e. D and Vd constant. This
corresponds for instance to the case where the number of doses per unit time (or
average number of doses per unit time in the stochastic case) evolves, while main-
taining everything else unchanged. One can see on Figure 4 that, when µ tends to
infinity, the variance in the deterministic frame reaches a plateau (the limit value
is 1
12
(
D
Vd
)2
), while the random situation leads to an unbounded variance. Hence
non-compliance has here a dramatic effect. When µ tends to 0, both variances
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behave as µ
2
and thus tend to 0. This simulation is however somewhat unrealistic
since it leads to an unbounded increase of the mean concentration when µ tends
to infinity. This is why, on Figure 5, we consider the case where µ varies but the
mean is kept constant. From Formula (12) and (2), we see that this simply trans-
lates into ensuring µ D
Vd
= constant. Here, we take µ D
Vd
= 0.23, which corresponds
to the parameters given in Table 1, and λ = 1 day. Figure 5 shows that both vari-
ances tend to 0 when µ tends to infinity. The speed of convergence is however
faster in the deterministic case ( 1
12µ2
) than in the random one ( 1
2µ
). When µ tend
to 0, both variances tend to infinity at same rate ( 1
2µ
).
Figure 4: Evolution of the variance as a function of µ in the deterministic (dashed)
and random (solid) cases, when all other parameters are kept constant. The value
µ = 1.9 corresponds to λ = 1 day.
A perhaps even more revealing comparison is to plot the values of λ in the
random model as a function of the ones of λ in the deterministic one that yield the
same variance: for instance, the point (1/24, 0.47) in the graph on Figure 6 means
that a compliant patient taking a dose every day will have same concentration
variability as a non compliant one taking in average a dose every 2.1 = 1/0.47
hours, when the mean dose per day and all other parameters are the same in both
situations.
Let us now present a comparison of the variance induced by non compliance
in the random instants model to the one entailed by differing elimination rates in a
fully compliant population. Similarly to Figure 6, we plot on Figure 7 the values
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Figure 5: Evolution of the variance as a function of µ in the deterministic (dashed)
and random (solid) cases, when the mean is kept constant.
Figure 6: Average number of doses per hour in the non-compliant case as a func-
tion of the number of doses per hour in the fully compliant one yielding same
variance for the concentration (elimination rate k = 0.022 h−1).
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of λ in the random model as a function of the variance σ2k of the elimination rates
in the model of Section 2.2 that yield the same variance of concentration when the
mean dose per day and all other parameters are the same in both situations. From
Formulas (4), (5), (9) and (10), we see that this amounts to setting:
λ =
k
2
(
eσ
2
k − 1) ,
where λ is the mean number of doses per hour of the non compliant patient, k is
both his elimination rate and the mean elimination rate in the population, and σ2k
is the variance of the elimination rates in the population. As an example, the point
(0.43, 0.02) on the graph means that the variance of concentration in a population
of compliant patients were the variance in elimination rates in 0.43 (as in [6]) will
be the same as for a single non compliant patient taking in average a dose every
49 (= 1/0.02) hours. Likewise, a single non compliant patient taking in average
a dose every day displays the same variance in concentration as a population of
fully compliant individuals with elimination rates variance equal to 0.24, i.e. a
coefficient of variation equal to 52%.
Note that exactly the same conclusions (including the numerical values) hold
if one considers a population where the clearance instead of only the elimination
rate follows a lognormal distribution, as Formulas (4) and (5) on the one hand, and
Formulas (6) and (7) on the other hand are similar upon replacing σk with σCl.
Let us now move to the regularity properties of the distribution of C. We show
in Section 3.2 that µ governs the smoothness of the distribution of the concentra-
tion: a larger µ translates into a better behaved concentration. More precisely, in
the long term, the cumulative probability distribution of drug concentration may
display two kinds of irregular behaviours. We just mention here that, when µ is
larger than one, the distribution is regular, while, when it is smaller than one, it is
singular at the origin. In practical terms, this amounts to quantifying in a precise
way the situations where the moments of intakes are too scarce with respect to the
elimination rate, resulting in a high probability of having too small a concentration
of drugs.
To illustrate this fact, we plot on Figure 8 histograms representing the empir-
ical probability distribution of C(T ) for a fixed time T , in two particular cases,
µ = 3 and µ = 0.5. The value ofD in each case was adjusted accordingly in order
to keep a constant mean. These histograms were obtained by simulating 50, 000
independent concentration paths in each scenario until time T , and dividing the
outcomes into 100 evenly spaced bins. The time T was chosen large enough so
15
Figure 7: Average number of doses per hour in the non-compliant case as a func-
tion of the variance of the elimination rates in a fully compliant population yield-
ing same variance for the concentration (elimination rate k = 0.022 h−1).
that the steady state has been reached (we took T = 100 max
(
1
λ
, 1
k
)
). The singu-
larity of the distribution of C at the origin in the case µ < 1 (second histogram)
manifests itself through the sharp spike in the first bin.
2.4 Continuous model with random intake instants and ran-
dom doses
In this section, we generalize the continuous model of the previous subsection to
allow for random doses. The idea is that the careless patient that has an irregular
schedule is likely to also mess up with the doses. For instance, he might take a
double dose to make up for a missing one (this is a particular case we consider in
Subsection 4.1). Formally, this translates into the fact that the quantity D in (8) is
now a random variable that may vary at each take rather than being a constant. In
other words, we assume now that the concentration, denoted Crd(t), is given by:
Crd(t) =
D
Vd
∞∑
i=0
Di exp(−ke(t− Ti))1 (t > Ti),
where D and Vd are constants, the (Ti)i∈N again form a Poisson process, and the
(Di)i∈N are random variables. At time i, the dose taken is thus DDi. It seems
16
Figure 8: Histogram of the distribution of C (left : µ = 3, right : µ = 0.5).
a = 0.2 b = 1.8 d1 = 0.4 d2 = 1.9 q1 = 0.6 q2 = 0.4
Table 2: Numerical values of the parameters of the random doses distributions
used in the simulations.
natural to assume that E(Di) = 1 (i.e on average, the patient takes the required
dose), that Di is supported onR+, and that it has compact support, i.e. the patient
cannot take arbitrarily large or small doses.
Once again we illustrate this model by showing on Figure 9 simulated sample
paths of the concentration in the two particular cases considered in Section 4: in
the first one, the random factors Di follow a uniform distribution on the interval
[a, b], and, in the second one, they follow a discrete distribution where the Di can
take on two values d1 and d2 with probabilities q1, q2. The PK parameters are the
ones given in Table 1, with an average time between intakes equal to λ−1 = 12 h.
The parameters for the random doses are given in Table 2.
As shown in Section 4, the mean value in this model is the same as in the
previous one, i.e.
E(Crd(t)) = E(C(t)).
The general expression for the variance is not illuminating (see Formula (25)).
However, under the assumption that the variance of Di does not depend on the
value of Ti, one obtains the simple equality:
Var(Crd(t)) = E(D21)Var(C(t)) = (1 + Var(D1))Var(C(t)).
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Figure 9: Eight sample paths of the concentration with Poisson distributed intakes
and random doses for the first 14 days, in two different scenarios (top: uniform
distribution, bottom: discrete distribution).
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Thus, random dosing results in multiplying the variance of the deterministic dose
case by E(D21). Estimating quantities such as P(|C −E(C)| > γE(C)) or P(C >
U), or comparing to the case of (population) full compliance is then readily done
once Var(D1) is known. In Subsection 4.1, we look at two particular cases where
Di is either uniformly distributed on a interval or takes values in a discrete set. We
characterize the situations leading to the largest variances for both distributions
(Formulas (30) and (31)).
In contrast to variability, random dosing does not affect the regularity of the
distribution of the long term concentration; this distribution is again smooth when
µ > 1 and is singular at 0 otherwise.
2.5 Discrete model with random intake instants and determin-
istic doses
We study a time discretized version of the random model presented in Subsection
2.3. The general idea is that, instead of taking the drug at arbitrary time instants
t ∈ R+, the patient will only do so at times which form a random subset of
{tnl = l/n, l ∈ N}, where n is a fixed number. There are two main reasons for
considering such a model. First, there are indeed natural situations where a time
discretization does occur. For instance, the medication must sometimes be taken
at precise moments, like before lunch. Many people will always have their lunch
at a fixed time, like certain workers or many older people. Second, as we show in
Subsection 5.3, the time discretized model tends to the continuous one when the
discretization step tends to 0. Thus, for n large enough, the practical difference
between both models vanishes. Nonetheless, the discrete model displays various
interesting and intriguing features that are not present in the continuous one. Let
us finally mention that considering the discretized model is very close to sampling
the concentration of the continuous one. Since blood concentrations cannot be
monitored continuously, the outcome of any clinical study is discrete in nature,
which gives further justification for the discrete model.
We show in Subsection 5.1 that the steady state discretized concentration S in
the situation where the patient takes a dose D with probability p independently at
each time j/n reads:
S =
D
Vd
∞∑
j=0
ajXj,
where the (Xj)j∈N are i.i.d. Bernoulli random variables with parameter p (i.e.
Xj = 0 with probability 1 − p and Xj = 1 with probability p). As explained in
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Subsection 5.1, one has to set p = λ
n
and a = exp(−k/n) to ensure correspon-
dence between the discrete and continuous models.
The mean and variance of the discretized concentration read:
E(S) =
D
Vd
p
1− a,Var(S) =
(
D
Vd
)2
p− p2
1− a2 .
These formulas allow one to draw the following conclusions:
• for a fixed mean equal to 1, the variance of S behaves as 1−p
p
1−a
1+a
. The
parameter µ is no more relevant here as both λ and k play an individual role
in this formula. Since we are interested in compliance, we consider the limit
cases where λ tends to 0 or infinity for a fixed k (and thus a fixed a). When
λ tends to 0, so does p, and the variance tends to infinity at speed 1
p
1−a
1+a
. This
is similar to the continuous model, as 1
p
is proportional to 1
µ
. Letting λ tend
to infinity amounts to letting p tend to 1, in which case the variance tends to
0, as expected.
• As above, the bound P(|S − E(S)| > γE(S)) 6 1
γ2
1−p
p
1−a
1+a
allows one
to assess the effect of non compliance on the variability of the long term
concentration.
The study of the regularity of the distribution is much more involved in the
discrete case than in the continuous one, as the former may display a fractal be-
haviour. Indeed, for some values of the parameters, the distribution will be ev-
erywhere singular. This means that the evolution of the distribution varies wildly
for most values of the concentration. In addition, the dichotomy smooth/singular
is not governed by µ alone, but by complex relations between λ, k, and the dis-
cretization step. More precisely, the cumulative probability distribution is singular
either when µ log(2) < p or when p ∈ [1
3
, 2
3
] and
k
n
> −
[
λ
n
log
(
λ
n
)
+
(
1− λ
n
)
log
(
1− λ
n
)]
.
It is absolutely continuous when p ∈ [1
3
, 2
3
] and
k
n
< −
[
λ
n
log
(
λ
n
)
+
(
1− λ
n
)
log
(
1− λ
n
)]
.
The situation is not fully understood for p outside the interval [1
3
, 2
3
]. See Subsec-
tion 5.4 for more details.
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2.6 Discrete model with random intake instants and random
doses
Similarly to Subsection 2.4, we consider a random dose variant of the previous
model. The steady state concentration now reads:
Srd =
D
Vd
∞∑
j=0
ajDjXj, (11)
which accounts for the fact that the stochastic dose at time j/n is equal to 0 or
DDj , where the random variables Dj are i.i.d. with mean 1 and take values in an
interval [dm, dM ] with 0 < dm < dM < ∞. The following facts hold concerning
the variability of Srd (see Subsection 6.1):
• the variance of Srd is the one of the discrete model with deterministic dose
case above, multiplied by
(
Var(D1)
1−p + 1
)
. It thus has a behaviour similar to
the one of S. Note however that, for all positive p, the effect of random
dosing on the variability is amplified in the discrete model, due to the factor
1
1−p . When p is close to 1 (the number of possible times for intake is only
slightly larger than the number of required ones), even a small variability in
dosing will have a drastic effect on the variance of the concentration.
• the probability that Srd differs from its mean by a factor γ is bounded as
follows: P
(|Srd − E(Srd)| > γE(Srd)) 6 (Var(D1)
1−p + 1
)
1
γ2
1−p
p
1−a
1+a
. The
same remarks as above apply.
Concerning regularity, and in contrast to what is observed in the continuous
time model, random dosing does affect it. Indeed, when dose randomness is
“large”, in the sense that dM
dm
is sufficiently large, then the distribution of con-
centration will be singular for most values of µ and p. See Subsection 6.3 for
more details, where it is shown that the cumulative probability distribution is sin-
gular with a nowhere dense support when a < dm
dm+dM
. This roughly means that,
in addition to the fact that the variations of Srd are very irregular, concentration
will only take some particular values in the interval [0, DdM
Vd
1
1−a ].
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2.7 Discrete model with random intake instants, random doses,
and random elimination rate
In this section, we consider yet another influence of randomness on the behaviour
of the concentration: in addition to random dosing and intake instants, we allow
the elimination rate to vary in a stochastic manner in time. While this is not
strictly related to the problem of non-compliance, it will obviously has an effect
on the variability of the concentration. The rationale for considering this effect is
that it seems plausible that, in general, k is not constant in time, and will evolve
according to various physiological factors. Of course, over small time intervals,
these evolutions will also be small, and are best seen as fluctuations around a
mean value. However, as we will see, even small fluctuations have a notable
impact on the variability and regularity of the concentration, in particular in the
case where µ is large. We shall restrict to the discrete setting, where a fairly
complete description may be obtained.
In details, we consider here a generalization of (11) where the elimination rate
at time j/n is equal to aZj instead of a, where the Zj are i.i.d. random variables
compactly supported with mean one (so that the mean elimination rate is a). The
asymptotic concentration for large times is denoted Srerd. It reads (see Section 7
for the derivation of this expression):
Srerd =
D
Vd
∞∑
j=0
(
j−1∏
n=0
Zn
)
ajDjXj.
The study of the variability of Srerd leads to the following conclusions:
• for a fixed mean equal to 1, the variance of Srerd tends to E(D21)−p
p
when µ→
0 in the case where E(Z21) remains bounded. However, if, say, E(Z21) ∼ ra2
with 0 < r < 1, then the variance tends to E(D
2
1)−p(1−r)
p(1−r) . The situation
when µ → ∞ depends more drastically on the behaviour of the random
elimination rate: when µ tends to infinity, the Zi must tend almost surely to
1. If for instance E(Z21) ∼ ( 1a2 )r again with 0 < r < 1, then the variance
tends to 1
1−r . However, if E(Z
2
1) ∼ 1+ 2pµ , then the variance tends to infinity
as µ
p
(the variance will also tend to infinity if E(Z21) tends to 1 more slowly
that 1+ 2p
µ
but remains smaller than 1
a2
). Thus, as soon as elimination varies
randomly in time, the variance of the concentration does not tend to 0 when
µ tends to infinity in this model, as it does for all other models considered
in this work. It may even increase without bounds in certain situations;
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• again, bounds for P(|Srerd−E(Srerd)| > γE(Srerd)) are given by the anal-
ysis of the variance above: when µ → 0, we get a finite bound equal to
E(D21)−p
p
or a similar term depending on the behaviour of the elimination
rate. Contrarily to all other models, when µ tends to infinity, the bound
does not tend to 0, which means that even for closely spaced intake instants,
a strong variability of the concentration will remain.
Using Proposition 11 of Subection 7.1, we plot on Figure 10 the variance of the
concentration as a function of the variances of the random elimination rate and
the random dose. As one can see, the added variability due to random elimination
has far greater impact on the variance of the concentration than the one due to
random dosing. Thus, “small” fluctuations in time of the elimination rate have
more impact than “large” fluctuations in dosing.
Figure 10: Variance of the concentration as a function of the variances of the
random elimination (Vrz) and the random dosing (Vrd), with values as in Table 1,
p = 0.8, 1/n = 24 hours (and thus a = 0.59).
Let us now turn to the regularity of the concentration: in most situations, it
will be irregular, except for moderate values of p and large µ. More precisely, the
cumulative probability distribution is singular when
E(log(Z)) < p/µ+ p log(p) + (1− p) log(1− p)
and it is absolutely continuous when the reverse inequality holds. In other words,
singularity will occur frequently when rate elimination randomness is “large”, in
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the sense that the logarithmic moment of the distribution of Z is sufficiently large
in absolute value. See Subsection 7.2 for more details.
This ends the overview of our models and their main features. The reader will
find in the next sections the precise derivations of the results mentioned above,
along with a more detailed analysis of the models.
3 Continuous model with random instants and de-
terministic doses
We study in this section the main properties of the random concentration given by
(8), that we recall here for convenience:
C(t) =
D
Vd
∞∑
i=0
exp(−k(t− Ti))1 (t > Ti),
where the Ti are Poisson distributed with parameter λ. Let us compute the
characteristic function ϕt of C(t). One version of Campbell theorem [8] states
that the process
∑
X∈Π f(X), where Π is a Poisson process on a measurable sub-
set S of R with mean measure ν and f a real-valued measurable function, is
absolutely convergent if and only if
∫
S
min(1, |f(x)|)ν(dx) < ∞, in which case
its characteristic function equals exp
(∫
S
(eiθf(x) − 1)ν(dx)). Applying this result
to S = R+, ν(dx) = λdx and f(x) = D
Vd
exp(−k(t− x))1 (t > x), one gets:
ϕt(θ) = exp
[
λ
∫ t
0
(
exp(iθ
D
Vd
e−k(t−x))− 1
)
dx
]
.
The change of variable u = D
Vd
e−k(t−x) yields:
Proposition 1. The characteristic function of C(t) is:
ϕt(θ) = exp
(
µ
∫ θ D
Vd
θ D
Vd
e−kt
eiu − 1
u
du
)
where µ = λ
k
.
The parameter µ is the inverse of the “oscillating parameter” considered in
[9]. Similarly to [9], we see that it plays a major role in the analysis of random
compliance.
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3.1 Variability of the concentration
From the characteristic function, one easily gets:
E(C(t)) = µ
D
Vd
(1− e−kt)
so that:
E(C(t))→t→∞ µD
Vd
. (12)
Likewise, the variance of C(t) reads:
Var(C(t)) =
µ
2
(
D
Vd
)2
(1− e−2kt).
When t tends to infinity,
Var(C(t))→t→∞ µ
2
(
D
Vd
)2
. (13)
Note that the convergences in (12) and (13) are exponential: only a few cycles
are needed before the steady state is reached. The same remark applies to all
convergences below.
In the next section, we show that, when t tends to infinity, C(t) itself also
converges to a well-defined random variable, denoted C, and investigate in details
some of its properties. Before that, we give a final result of interest pertaining
to the variability of the concentration in the non-compliant case. More precisely,
the following proposition yields a bound on the probability that the concentration
exceeds a given (large) level, or departs significantly from its mean.
Proposition 2.
P(C(t) > U) 6 7
12U2
µ
(
D
Vd
)2 (
1− e−kt) (1 + 2µ− 2µ e−kt + e−kt) . (14)
P(C > U) 6 7
6U2
(
D
Vd
)2
µ
(
µ+
1
2
)
. (15)
P(|C − E(C)| > γE(C)) 6 1
2µγ2
. (16)
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Of course, the bound in (16) is of interest only if µ and/or γ is sufficiently
large.
Proof.
This is a direct application of the classical bound (see, e.g. [11], p. 209):
P(C(t) > U) 6 7U
∫ 1
U
0
(1− Re(ϕt(θ))) dθ,
valid for U > 0, and where Re denotes the real part. Indeed,
Re(ϕt(θ)) = cos
(
µ
∫ θ D
Vd
θ D
Vd
e−kt
sin(u)
u
du
)
exp
(
µ
∫ θ D
Vd
0
cos(u)− 1
u
du
)
,
and routine estimates yield (14). (15) follows in a similar way. Finally, (16) is
simply Chebychev inequality.
Note that, in the deterministic case (full compliance), and with the definition
of the variance given in Subsection 2.1, one has, in place of (16):
P(|Cd(t)− E(Cd)| > γE(Cd)) 6 1
2µγ2
e
1
µ − 2µe 1µ + 2µ+ 1
e
1
µ − 1
. (17)
This is another quantitative way to measure by how much the probability of
differing from the mean will be larger in the non-compliant case: in particular,
when µ is ”large”, the right-hand side in the inequality above behaves as 1
12µ2γ2
.
This gives a bound six times smaller than in the non-compliant case. This was
illustrated on Figure 3.
3.2 Regularity of the limit distribution
In this section, we study the long term behaviour of the drug concentration, i.e. the
distribution function of the limit C := limt→∞C(t), where the limit is understood
to be taken in the sense of convergence in law. Indeed:
Proposition 3. The random variables C(t) converge in distribution, when t tends
to infinity, to a well defined random variable C whose characteristic function
equals:
ϕ(θ) = exp
(
µ
∫ θ D
Vd
0
eiu − 1
u
du
)
.
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Proof.
When t tends to infinity, ϕt tends pointwise to ϕ, which is continuous at θ = 0.
By Levy theorem, this implies the result.
We shall denote by F the cumulative probability distribution ofC, i.e. F (x) =
P(C 6 x). It is convenient to have an explicit expression for C. However,
one cannot directly let t tend to infinity in (1) to obtain a representation of the
limit concentration. One way around this difficulty is to notice that the distri-
bution of the intake times falling in the interval [0, t] is invariant by time re-
versal: looking ”‘backwards”’ in time, one sees that C(t) has the same law as
C ′(t) = D
Vd
∑∞
i=0 exp(−kTi))1 (t > Ti) ; as t tends to infinity, the random vari-
ables C ′(t) converge almost surely to C ′ = D
Vd
∑∞
i=0 exp(−keTi), which therefore
has the same distribution as C.
In the sequel, we shall write
C =
D
Vd
∞∑
i=0
exp(−kTi). (18)
since we are only interested in distributional properties.
One may rewrite ϕ as follows:
ϕ(θ) =
(
D
Vd
)−µ
e−µγe−
iµpi
2 θ−µ exp
(
−µ
∫ ∞
1
e
i D
Vd
θu
u
du
)
, (19)
where γ is Euler’s constant.
Proposition 4. When θ tends to infinity,
ϕ(θ) ∼
(
D
Vd
)−µ
e−µγ+iµ
pi
2 θ−µ +O(θ−µ−1). (20)
Proof.
When θ tends to infinity,
∫ D
Vd
θ
0
sin(u)
u
du tends to
∫∞
0
sin(u)
u
du = pi
2
, while:∫ D
Vd
θ
0
cos(u)− 1
u
du ∼ −γ − log(D
Vd
θ) +O(
1
θ
).
27
In particular,
∫ D
Vd
θ
0
eiu−1
u
du − ipi
2
+ γ + log( D
Vd
θ) tends to 0 and thus we may
exponentiate the equivalents to get the announced result.
In particular,
|ϕ(θ)| ∼ Kθ−µ, θ →∞, (21)
where K is a constant (in the sequel, K will always denote a finite positive con-
stant, which may change from line to line).
From this, we get that F has an L2 density2 if and only if µ > 1/2.
Recall the following well-known properties (see, e.g. [16], p. 40): let α ∈
(0, 1). Then:
1. 1
T
∫ T
−T |ϕ(θ)|2dθ = O(T−α)⇒ F ∈ Lip(α2 ),
2.
∫∞
1
θ α−1|ϕ(θ)|dθ <∞⇒ F ∈ Lip(α).
From 2 and (21), one gets F ∈ Lip(µ − ε) for µ < 1 and any ε > 0. One
easily verifies that 1
T
∫ T
−T |ϕ(θ)|2dθ is equivalent to KT−2µ when µ < 12 and to
KT−1 when µ > 1
2
. From this and 1, one deduces that F ∈ Lip(µ) for µ < 1
2
.
A more localized information on the regularity of F may be obtained from its
Laplace transform ψ(u), whose expression also follows from Campbell theorem
(since C is positive, the conditions of Campbell theorem are verified):
ψ(u) = exp
[
µ
∫ u D
Vd
0
(
e−s − 1
s
)
ds
]
.
It is facile to deduce from this that ψ(u) ∼ e−µγ−µ log( DVd )u−µ when u tends to
infinity. A classical Tauberian theorem (see, e.g. [5], p.445) then entails that:
F (ε) ∼ e
−µγ−µ log( D
Vd
)
Γ(µ+ 1)
εµ, ε→ 0.
Thus, F has a finite non vanishing derivative at 0 exactly when µ = 1. Fur-
thermore, it is differentiable at 0 when µ > 1 and not differentiable at 0 when
µ < 1. In addition, 0 is the only possibly singular point of F . Indeed, the follow-
ing proposition shows that F is smooth at any x > 0.
2This means that the integral of the square of the probability density function is finite.
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Proposition 5. For any x > 0,
F (x+ ε)− F (x) = O(ε)
when ε→ 0+.
The proof is given in section 8.1.
The practical meaning of these results is that, exactly when λ < k, the instants
of intakes are too scarce (with respect to the elimination rate), resulting in a high
probability of having too small a concentration of drugs.
4 Continuous model with random instants and ran-
dom doses
In this section, we consider the generalization of the continuous model of Section
3 to allow for random doses. The concentration, denoted Crd(t), now reads:
Crd(t) =
D
Vd
∞∑
i=0
Di exp(−ke(t− Ti))1 (t > Ti), (22)
where the (Ti)i∈N form again a Poisson process, and the (Di)i∈N are random
variables. At time Ti, the dose taken is DDi and we assume that E(Di) = 1, that
Di is supported on R+, and that it has compact support (although we shall need
only weaker assumptions).
The process Crd(t) thus defined is a marked Poisson process. In this work, we
shall assume that the (Di)i∈N are independent and identically distributed random
variables, where each Di may depend on Ti but is independent from the (Tj)j 6=i.
This makes sense from a pharmacokinetical point of view, since it seems plausible
that the patient will not adjust his dose at time Ti on the basis of his past or future
behaviour except for the time lag from the previous take, although it would maybe
be desirable to let Di depend also on Di−1. We denote by ν(T, .) the conditional
distribution of Di knowing that Ti = T . Our assumptions makes it possible to ap-
ply a generalized form of Campbell theorem [8] to the effect that the characteristic
function ϕrdt of C
rd(t) is given by:
ϕrdt (θ) = exp
{
λ
∫
R+×A
[
exp(iθ
D
Vd
ue−k(t−x)1 (t > x))− 1
]
ν(x, du)dx
}
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= exp
{
λ
∫ t
0
∫
A
[
exp(iθ
D
Vd
ue−k(t−x))− 1
]
ν(x, du)dx
}
, (23)
where A ⊂ R∗+ is the support of the Di.
4.1 Variability of the concentration
From (23), one deduces easily the mean and variance of Crd:
(ϕrdt )
′(θ) = ϕrdt (θ)λ
∫ t
0
∫
A
i
D
Vd
ue−k(t−x) exp(iθ
D
Vd
ue−k(t−x))ν(x, du)dx
and thus
(ϕrdt )
′(0) = iλ
D
Vd
∫ t
0
e−k(t−x)
∫
A
uν(x, du)dx
= iλ
D
Vd
∫ t
0
e−k(t−x)Ex(D1)dx
= iλ
D
Vd
∫ t
0
e−k(t−x)dx
= iµ
D
Vd
(1− e−kt),
where Ex(D1) denotes the expectation of Di knowing that Ti = x, which is equal
to one for any x by assumption. Thus we find that, not surprisingly:
E(Crd(t)) = E(C(t)). (24)
Likewise,
(ϕrdt )
′′(θ) = ϕrdt (θ)λ
2
(∫ t
0
∫
A
i
D
Vd
ue−k(t−x) exp(iθ
D
Vd
ue−k(t−x))ν(x, du)dx
)2
+
ϕrdt (θ)λ
∫ t
0
∫
A
−
(
D
Vd
)2
u2e−2k(t−x) exp(iθ
D
Vd
ue−k(t−x))ν(x, du)dx
Using that, by definition,
∫
A
u2ν(x, du) = Ex(D21), this entails:
(ϕrdt )
′′(0) = −E(C(t))2 − λ
(
D
Vd
)2 ∫ t
0
e−2k(t−x)
∫
A
u2ν(x, du)dx
= −E(C(t))2 − λ
(
D
Vd
)2 ∫ t
0
e−2k(t−x)Ex(D21)dx
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or, since (ϕrdt )
′′(0) = −E(C(t))2 − Var(Crd(t)),
Var(Crd(t)) = λ
(
D
Vd
)2 ∫ t
0
e−2k(t−x)Ex(D21)dx.
However,
Ex(D21) = Varx(D1) + Ex(D1)2 = Varx(D1) + 1
(Varx(D1) denotes the variance of Di knowing that Ti = x) and
λ
(
D
Vd
)2 ∫ t
0
e−2k(t−x)dx = Var(C(t)),
thus
Var(Crd(t)) = Var(C(t)) + λ
(
D
Vd
)2 ∫ t
0
e−2k(t−x)Varx(D1)dx. (25)
If we assume that the variance of Di does not depend on the value of Ti, i.e.
Varx(D1) = Var(D1), we get:
Var(Crd(t)) = E(D21)Var(C(t)) = (1 + Var(D1))Var(C(t)). (26)
Thus, random dosing results in multiplying the variance of the deterministic dose
case by E(D21). It is then easy to obtain inequalities similar to (14), (15), and (16)
for the random dose case.
Two particular cases may be of special interest:
• Discrete distribution: the (Di) assume the values {d1, . . . , dm} ⊂ R+ with
probabilities q1, . . . , qm, independently of the Ti. We denote by C
rd,d
t and
ϕrd,dt the concentration and characteristic functions. Then:
ϕrd,dt (θ) =
m∏
j=1
exp
(
qjµ
∫ θ D
Vd
dj
θ D
Vd
dje−kt
eiu − 1
u
du
)
, (27)
which has an obvious interpretation and may be written as:
ϕrd,dt (θ) =
m∏
j=1
ϕt(qjµ, djθ) (28)
where we have written ϕt(qjµ, .) instead of ϕt(.) for the characteristic func-
tion in the deterministic-dose case but with parameter qjµ instead of µ. This
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equality also holds when t tends to infinity, yielding the long term concen-
tration characteristic function. The variance is given by:
Var(Crd,d(t)) = E(D21)Var(C(t)) =
(
m∑
j=1
qjd
2
j
)
Var(C(t)). (29)
It is of interest to characterize the situation giving the largest variance among
all admissible random dosings with arbitrary m, qi, and di. In other words,
we look for the value of Vmax := max Var(Crd,d(t)) subject to m > 1,
(q1, . . . , qm) ∈ [0, 1]m with at least two qi non zero and
∑m
j=1 qi = 1,
(d1, . . . , dm) ∈ [a, b] with b > a > 0, and
∑m
j=1 qidi = 1. It is easily shown,
for instance using Lagrange multipliers, that the maximum is reached for
m = 2 and d1 = a, d2 = b. In this case,
Vmax = (a+ b− ab)Var(C(t)). (30)
Thus the worst-case situation is when the patient “oscillates” between two
dosings whose average is the prescribed one.
• Uniform distribution: the Di are uniformly distributed over [a, b] ⊂ R+,
independently of the Ti. We denote by C
rd,u
t and ϕ
rd,u
t the concentration
and characteristic function. In this case, one computes:
ϕrd,ut (θ) = exp
{
λ
b− a
∫ t
0
∫ b
a
[
exp(iθ
D
Vd
ue−k(t−x))− 1
]
dudx
}
= exp
{
− iµ
b− a
∫ θ D
Vd
θ D
Vd
e−kt
[
eibv − eiav
v2
− ib− a
v
]
dv
}
,
This last integral is easily seen to be convergent when t tends to infinity,
which gives us the long term concentration characteristic function. Note
that ϕrd,u tends to ϕ when the couple (a, b) tends to (D,D): the concen-
tration with random doses uniformly distributed on [a, b] tends in law to the
concentration with fixed dose D.
The variance is given by:
Var(Cu(t)) = E(D21)Var(C(t)) =
a2 + ab+ b2
3
Var(C(t)). (31)
From this equation it is easily seen that the choice of [a, b] maximizing the variance
under the constraint E(Di) = 1 is a = 0, b = 2, as expected.
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4.2 Regularity of the limit distribution
We first consider the two cases of discrete and uniform random dosing.
• Discrete distribution
From (28), one easily sees that:
|ϕrd,dt (θ)| ∼
m∏
j=1
(djθ)
−qjµ = Kθ−µ
when θ tends to infinity, where K is a constant.
• Uniform distribution
The modulus of ϕrd,u(θ) = limt→∞ ϕ
rd,u
t (θ) equals:
|ϕrd,u(θ)| = exp
{
µ
b− a
∫ θ D
Vd
0
[
sin(bv)− sin(av)
v2
− b− a
v
]
dv
}
= exp
{
µ
b− a
∫ θ D
Vd
0
[
sin(bv)
v2
− b
v
]
dv
}
× exp
{
µ
b− a
∫ θ D
Vd
0
[
−sin(av)
v2
+
a
v
]
dv
}
.
Now, for large enough θ,
exp
{
µ
b− a
∫ θ D
Vd
0
[
sin(bv)
v2
− b
v
]
dv
}
= exp
{
µ
b− a
∫ 1
0
[
sin(bv)
v2
− b
v
]
dv
}
× exp
{
µ
b− a
∫ θ D
Vd
1
sin(bv)
v2
dv
}
exp
{
− µ
b− a
∫ θ D
Vd
1
b
v
dv
}
.
The first factor of the product in the right-hand side above is a constant.
When θ tends to infinity, the second factor tends to another constant. Finally,
the third factor behaves as a constant times θ−µ
b
b−a . As consequence,
|ϕrd,u(θ)| ∼ Kθ−µ bb−a θµ ab−a = Kθ−µ
when θ tends to infinity.
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Thus in both particular cases above, we recover the same behaviour for the charac-
teristic function as in the deterministic-dose case. As the next proposition shows,
this is in fact a general feature of all random dosings provided ν(x, du) does not
depend on x, with an additional mild condition:
Proposition 6. Assume that ν(x, du) = ν(du) and that
∫
A
log(u)ν(du) < ∞.
Then
ϕrd(θ) ∼ Kθ−µ
when θ tends to infinity, where K ∈ C is a constant.
The proof of this proposition may be found in Section 8.2
Proposition 6 shows that random dosing, at least when the distribution of the Di
is independent of the Ti, does not alter the regularity of the distribution of the long
term concentration as compared to the deterministic dose case.
5 Discrete model with random instants and deter-
ministic doses
We study in this section a discretization in time of the model of Section 3: instead
of taking the drug at arbitrary time instants t ∈ R+, we assume that the patient
will only do so at times which form a random subset of {tnl = l/n, l ∈ N}, where
n is a fixed number.
We shall first rewrite the drug concentration in this discrete setting. It will ap-
pear that the discretized concentration Cd has the same law as a classical measure
called infinite Bernoulli convolution. We will study the variability of the dis-
cretized concentration. Then we will show that, when n tends to infinity, the dis-
cretized model tends distribution-wise to the continuous time one. We will finally
study the regularity of the long term behaviour of the discretized concentration
for n fixed or tending to infinity, and show that it is, under certain circumstances,
singular.
5.1 The discretized concentration
Let us explain in detail how to discretize the continuous model of Section 3 in a
meaningful way. Let h = 1
n
> 0 be the discretization step. We assume that the
intakes can only occur at times tj = jh, j ∈ N. Let Xj be the random variable
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that takes on the value 1 if the patient takes the drug at time tj , and 0 otherwise.
From a general point of view, the discrete analogue of the Poisson process is
the Bernoulli process. Indeed, in the continuous framework, the Poisson process
is the only counting process which has stationary and independent increments.
The only discrete counting process with the same property is the Bernoulli pro-
cess. In terms of waiting times, this amounts to replacing the i.i.d., memoryless,
exponential random variables Sn = Tn+1 − Tn, by i.i.d. random variables fol-
lowing a geometric distribution (recall that the geometric distribution is the only
memoryless discrete distribution)3.
We are thus led to consider a sequence of i.i.d. Bernoulli random variables
(Xj)j>1 as follows:
Xj = 0 with probability 1− p
Xj = 1 with probability p.
In the discrete model, the expected number of intakes per unit time is p/h, so
in order to agree with the continuous model, one has to choose p = λh. Note that,
for the model to make sense, p cannot be larger than one, which translates into:
λh 6 1. (32)
This simply means that if the required number of doses per month is, say, 10,
then there must be least 10 discrete times in the month when intake is possible.
The closer p is to 1, the more constrained the situation is. We shall see various
instances of this below, most notably in section 6.1.
At a fixed time tn and for any 0 6 j 6 n, the contribution of the j-th intake to
the current concentration is
D
Vd
exp(−k(tn − tj))Xj = D
Vd
an−jXj
where a = exp(−kh) = exp(−p/µ) is the elimination rate for one time step.
Therefore the total concentration at time tn is given by
Cn =
D
Vd
n∑
j=0
an−jXj
3One may also argue by considering what happens in time intervals of size h: let Xj be the
number of time instants where a drug intake takes place in such an interval (in the continuous
model). For small h, Xj is approximately distributed as a Bernoulli random variable.
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(Note that the sequence (Cn) satisfies the natural recurrence equation Cn+1 =
aCn +Xn+1 which shows that (Cn) is a Markov chain onR+.)
Since the random variablesX0, ..., Xn are independent, they are exchangeable,
and in particular the vector (X0, ..., Xn) has the same distribution as the reversed
vector (Xn, ..., X0). Hence Cn is equal in distribution to
Sn =
D
Vd
n∑
j=0
ajXj.
The sequence (Sn) converges almost surely to the random variable
S =
D
Vd
∞∑
j=0
ajXj.
This implies that Cn converges in distribution to S. In the sequel, we will only be
interested in the properties of the steady state discrete concentration S.
5.2 Variability of the concentration
One computes easily the mean Edisc and variance Vdisc in the discretized model:
Edisc := E(S) =
D
Vd
p
1− a, (33)
Vdisc := E(S2)− (E(S))2 =
(
D
Vd
)2
p− p2
1− a2 . (34)
As we shall see in the next section, the discrete model tends in law to the
continuous one when p tends to 0. For now, we simply remark that, indeed, Edisc
tends to µ D
Vd
and Vdisc tends to µ2 (
D
Vd
)2 when p tends to 0, i.e. the mean and variance
of (12) and (13) (note that, when p→ 0, a ∼ 1− p
µ
tends to 1).
For Edisc constant, say Edisc = 1, the variance in the discrete model equals
1−p
p
1−a
1+a
. See Subsection 2.5 for a discussion of the limit cases λ→ 0 and λ→∞.
As a consequence of Chebychev inequality we have (compare (16)):
P(|S − E(S| > γE(S)) 6 1
γ2
1− p
p
1− a
1 + a
. (35)
In the sequel of this section, we will set D
Vd
= 1 for simplicity, as this quantity
will not play any role in the rest of the analysis of Section 5.
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All the quantities above are functions of the discretization step 1
n
, or, equiv-
alently, of p. We shall indicate this dependency by adding a subscript p to the
various quantities considered below, i.e. we write Sp, . . .
Sp is an infinite sum of independent Bernoulli random variables, thus its law is
an infinite convolution of Bernoulli distribution, hence its name ”‘infinite Bernoulli
convolution”’. By writing:
S =
D
Vd
(
aX1 +
∞∑
j=2
ajXj
)
,
and conditioning on the value of X1, it is easily seen that the distribution Fp of
Sp is the unique cumulative probability distribution solution to the self-similarity
equation:
Fp(x) = (1− p)Fp(x
a
) + pFp(
x
a
− 1). (36)
We denote bymp the associated measure, i.e. mp[0, x] = Fp(x). This measure
has been studied in depth in fractal analysis as the invariant measure of the Iterated
Function System (IFS) (W1,W2) where W1(x) = ax,W2(x) = ax + 1, and
associated probability vector (1− p, p).
By Fourier transforming (36), one gets that the characteristic function ϕp of
Sp verifies:
ϕp(θ) =
[
1 + p
(
eiaθ − 1)]ϕp(aθ),
and, using the fact that ϕp(0) = 1:
ϕp(θ) =
∞∏
j=1
[
1 + p
(
eia
jθ − 1
)]
. (37)
5.3 Limit when the discretization step tends to 0
In this subsection, we investigate the behaviour of Sp when n tends to infinity.
Equivalently, we let p (the probability of drug intake at any given time i
n
) tend to
0. Note that this also equivalent to letting a tend to 1.
We denote:
• Yj = ajXj ,
• SJp =
∑J
j=1 Yj .
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When J tends to infinity, SJp converge almost surely to Sp =
∑∞
j=1 Yj .
The following proposition shows that the discretized model tends to the con-
tinuous one defined in Section 3 when the discretization step tends to 0.
Proposition 7. Sp =
∑∞
j=1 Yj tends in law to C when p tends to zero.
The proof of this result is given in section 8.3.
In practical terms, this means that, as long as we are only interested in dis-
tributional properties of the concentration, we may consider the discrete model
instead of the continuous one provided p is chosen small enough. Note however
that the discrete model with arbitrary value of p is interesting in its own right.
5.4 Regularity of the limit distribution
For each fixed p, Sp is an infinite Bernoulli convolution. There is huge literature
on the regularity of Bernoulli convolutions [4, 12, 13, 14, 15, 17]. The regularity
of the discretized model will display a sharp contrast depending on whether a < 1
2
or a > 1
2
:
• when a < 1
2
, the distribution of Sp is singular with respect to the Lebesgue
measure. More precisely, the Hausdorf dimension of its support is equal to
− log(2)
log(a)
< 1 (recall that the Hausdorf dimension measures the “size”, in a
certain sense, of the support of the measure, i.e. where it is concentrated).
This means that the set of possible values taken by the concentration is ex-
tremely sparse and does not form a continuum. In addition, the probability
of being in an interval varies in a very non smooth way.
Note that a < 1
2
is equivalent to p > µ ln(2) or hk > ln(2) (recall that
h is the discretization step). This translates into the fact that, for fixed k,
the time instants at which the patient is supposed to take his drugs are suf-
ficiently spaced, and that he forgets to do so randomly at some of these
instants. Alternatively, for a fixed h, the decay rate k must be sufficiently
large. Note also that, in view of (32), this is possible only if µ < 1
log(2)
.
In this situation, the cumulative probability distribution of the concentra-
tion will thus be highly irregular : it will vary erratically, taking only very
particular values, and the probability that it ranges in some interval varies
wildly when the interval changes.
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• In contrast to the case a < 1
2
, where everything is known about the distri-
bution of Sp, the case a > 12 is much more delicate and is not completely
settled, although great progress has been done in recent years. [17] (see
also [14]) has proved that the distribution of Sp is absolutely continuous for
Lebesgue-almost all a in (1
2
, 1) when p = 1
2
. This means that the distri-
bution of the concentration has a probability density: in other words, the
probability that the concentration ranges in some interval varies smoothly
when the interval changes. This result has been extended to get absolute
continuity for p ∈ [1
3
, 2
3
] and almost all a ∈ [pp(1 − p)(1−p), 1) in [15]. On
the other hand, the distribution is singular for all a < pp(1 − p)(1−p) with-
out restrictions on p. In terms of pharmacokinetical parameters, singularity
translates into:
kh > − [λh log(λh) + (1− λh) log(1− λh)] . (38)
Unlike the case of the continuous model, regularity cannot be described
solely in term of the ratio µ = λ
k
. Instead, both variables λ and k must
be considered independently. However, in view of (38), it is natural to use
the reduced quantities λ˜ := λh and k˜ = kh. These are natural discrete
counterparts of λ and k in this model. Figure 11 pictures the regions where
the concentration behaves smoothly or erratically in the parameter space
(λ˜, k˜).
The situation where the discretization step h tends to 0, or equivalently a
tends to 1 and p tends to 0 is of particular interest to us, since, as shown
above, the discretized model tends to the continuous one in this limit. Un-
fortunately, none of the results above about absolute continuity apply in our
frame when we consider “small” p: indeed, with a = exp(−p/µ) and p
tending to zero, we have a > pp(1− p)(1−p) for all sufficiently small p irre-
spective of the value of µ, as is easily shown by a Taylor expansion. Thus
the condition ensuring singularity is not in force, while the result on abso-
lute continuity result are not available because p is too small. A recent result
may however be of interest for us: [18] has proved absolute continuity for p
sufficiently small and almost all a > 1− 0.6p. For small p, a ∼ 1− p
µ
, and
this hints that, for almost every value of µ above a certain threshold µ∗(p),
such that µ∗(p) → 5/3 when p → 0, the distribution of the concentration
should have a density. Again, we find that a large µ translates into a better
behaved concentration.
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Figure 11: For values of k˜ = kh below the curve, the distribution of the concen-
tration will be singular. Above the curve, and for λ˜ = λh between 1
3
and 2
3
, it will
be absolutely continuous for almost all k.
6 Discrete model with random instants and random
doses
In the discrete case, the random dose model takes the following form:
• We still have a sequence of i.i.d. Bernoulli random variables (Xj)j>1 with
parameter p, which mark the random instants of drug intake.
• To account for the random dosing, we consider a sequence of i.i.d. ran-
dom variables (Dj)j>1, such that again DDj will represent the doses. The
(Dj)j>1 have distribution ν compactly supported on R∗+. We make the as-
sumption that E(Dj) = 1, i.e., on average, the patient takes the prescribed
dose. We also assume that the Dj are independent of the Xj . We let
[dm, dM ] denote the support of ν. To avoid degenerate cases, we assume
that, for any ε > 0, there are an infinitely many indices j, j′ for which
Dj < dm + ε and Dj′ > dM − ε.
• As previously, we set a = e−p/µ.
Using the same exchangeability argument as in section 5.1, we are led to consider
the sum D
Vd
∑n
j=1 a
jDjXj , which converges almost surely (with respect to B × ν,
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where B is the law of the Xj) to:
Srdp =
D
Vd
∞∑
j=1
ajDjXj. (39)
The characteristic function of Srdp is easily obtained by conditioning on the values
of Xj . Indeed,
E(eajDjXjθ) = 1− p+ pϕD(ajθ)
where ϕD is the characteristic function of D1. As a consequence:
ϕrdp (θ) =
∞∏
j=1
[
1− p+ pϕD(ajθ)
]
. (40)
As before, we investigate the variability in this model, the limiting behaviour
when p tends to 0, and finally the regularity of the distribution of the long-term
concentration.
6.1 Variability of the concentration
One easily computes the mean and variance in this model:
Proposition 8.
Erddisc = Edisc =
D
Vd
p
1− a,
V rddisc =
(
Var(D1)
1− p + 1
)
Vdisc.
This is similar to what was found in the continuous model (formula (26)), i.e.
the added variability brought by random dosing enters in a multiplicative way. As
noted in Subsection 2.6, the effect of random dosing on the variability is however
amplified in the discrete model, due to the factor 1
1−p .
Bounds like the ones in (14), (15) and (16) may then be obtained.
6.2 Limit when the discretization step tends to 0
Proposition 9. Srdp converges in law to Crd when p tends to 0.
The proof is similar to the one in the deterministic dose model, and is omitted.
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6.3 Regularity of the limit distribution
The problem of characterizing the regularity of the long term concentration is a
hard one in general and we only give partial results of interest for us. Results
recalled in Section 1 and Theorem 2 of [1], translated to our setting, entail the
following:
Proposition 10. 1. If a > dM
dm+dM
, then the support of the concentration is an
interval.
2. If a < dm
dm+dM
, then the support of the concentration is nowhere dense. Its
Hausdorf dimension is equal to − log(2)
log(a)
.
Note that, in the singular case, the dimension of the support is the same as in
the deterministic dose case, i.e. random dosing does not increase irregularity.
The proof of this result is given in Section 8.4.
7 A model with random elimination rate
We consider a final model where not only the intake instants and doses are random,
but also is the elimination rate: in other words, we take into account the fact that k
may take different values at different times. Of course, as noted in Subsection 2.7,
the variations of k will be very small for a typical patient. It is however interesting
to investigate their impact on the variability and regularity of concentration, and
to compare them with other effects of non compliance. As we will see, even small
fluctuations of the elimination rate have a notable effect.
We will only consider a discrete version of the model. Precisely, our random
time, random dose and random elimination model takes the following form:
• we still have a sequence of i.i.d. Bernoulli random variables (Xj)j>1 with
parameter p, which mark the random instants of drug intake;
• random dosing is modeled by a sequence of i.i.d. random variables (Dj)j>1
as in section 6;
• to account for the random elimination rate, we replace the elimination factor
a = e−kh by a sequence of i.i.d. random variables Z˜i ∈ (0, 1) with mean a.
In other words, at each discrete time, the elimination, instead of being fixed
and equal to a, varies randomly “around” a. The condition on the support
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of the Z˜i is natural in view of the fact that they represent elimination rates.
It will be more practical to consider the reduced random variables Zi = Z˜ia .
We write G for the distribution of the Zi. The constraints on Z˜i entail that
0 < Zi <
1
a
and E(Zi) = 1. We note for further reference that this also
implies:
1 6 E(Z2i ) <
1
a2
. (41)
We will let G denote the product measure GN.
We set Yj =
(∏j
n=1 Zn
)
ajDjXj , and we investigate the behaviour of the almost
sure limit (with respect to G):
Srerdp =
D
Vd
∞∑
j=0
Yj =
D
Vd
∞∑
j=0
(
j−1∏
n=0
Zn
)
ajDjXj. (42)
Let us briefly explain how we obtain (42): the concentration at time tn = nh is
equal to:
Cn =
D
Vd
n∑
j=0
(
n∏
i=j+1
Z˜i
)
DjXj =
D
Vd
n∑
j=0
(
n∏
i=j+1
aZi
)
DjXj
By exchangeability, Cn has the same law as Sn:
Sn =
D
Vd
n∑
j=0
(
j−1∏
i=0
aZi
)
DjXj
which indeed tends in law to Srerdp given by (42), and is our random time, random
dose and random elimination rate long term concentration. The distribution of this
random variable coincides with the one of the invariant measure of the IFS with
random mapsW1(x) = Zax,W2(x) = Zax+1, and associated probability vector
(1 − p, p), where Z has distribution G. We shall denote by FZp the conditional
distribution of Srdp knowing (Z1, Z2, . . .). Such an IFS has been studied in depth
in [13]. The assumptions4 in [13] (translated to our situation) are as follows:
1. All the Zi are independent of the Xj .
4the assumptions of [13] which are automatically satisfied in our setting are not mentioned
here.
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2. The random variable Z has an absolutely continuous distribution supported
on R∗+, with density bounded from above by
C
x
for all x > 0, where C is a
constant.
3. The IFS is contracting on average, which translates into its Lyapunov ξ
exponent being negative. In our case, since the two contraction ratios are
the same, this simply reads ξ = E(log(Z)) + log(a) < 0.
Assumption (1) is certainly fulfilled in our frame: the random elimination rate
does not depend on the fact that the patient takes his dose or not. The bounded
density requirement in condition (2) is automatically verified here since Z has
compact support. Assumption (3) is also fulfilled, since E(Z) = 1 and, by Jensen
inequality, this entails E(log(Z)) 6 0 < p/µ = − log(a) (as mentioned above,
requiring E(Z) = 1 is natural in our frame).
As before, we first proceed to investigate the variability in this model, and then
the regularity of the distribution of the long-term concentration.
7.1 Variability of the concentration
Proposition 11.
Ererddisc = Edisc =
D
Vd
p
1− a,
V rerddisc =
(
D
Vd
)2 [
p
1− a2E(Z2)
(
E(D21) +
2pa
1− a
)
−
(
p
1− a
)2]
.
The proof of this result is given in Section 8.5.
See Subsection 2.7 for an asymptotic analysis of the variance in the cases µ → 0
and µ→∞ and a comparison between the various sources of randomness.
7.2 Regularity of the limit distribution
Theorem 2.1 and proposition 2.2 in [13] yield a complete answer regarding the
regularity of FZp (i.e. the distribution conditioned on G). Let H = −p log(p) −
(1− p) log(1− p) denote the entropy of the measure mp associated to Fp. Then:
• if −ξ < H , FZp is absolutely continuous, G-almost surely.
• if −ξ > H , FZp is singular, G-almost surely. Its Haussdorf dimension is
equal to H−ξ .
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Translated to our setting, the condition for the distribution of the concentration
to be (almost surely) singular is:
E(log(Z)) < p/µ+ p log(p) + (1− p) log(1− p),
with the distribution being absolutely continuous when the reverse inequality
holds.
Depending on the relative values of E(log(Z)), µ, and p, one may thus observe
two drastically distinct behaviours. Note however that, in the ”interesting” cases
p→ 1 and p→ 0, the distribution will always be singular, for a wide range of the
admissible values of E(log(Z)) and µ, or even irrespective of these values:
• When p is large, we are in a situation where the instants at which the patient
is supposed to take his drugs are sufficiently spaced in time. If p is close to
1, then p/µ+p log(p) + (1−p) log(1−p) is positive (for reasonable values
of µ) and thus larger than E(log(Z)).
• When p tends to 0 (i.e. in the continuous limit), p/µ + p log(p) + (1 −
p) log(1 − p) also tends to 0, and thus, for any given distribution G, there
exists p0 = p0(G) > 0 such that for all p < p0, the distribution of concen-
tration will be singular.
On the other hand, theorem 2.3 in [13] implies that, if:
E(log(Z)) > p/µ− | log(p2 + (1− p)2|,
then the distribution will be G-almost surely absolutely continuous with an L2
density, and if:
E(log(Z)) > p/µ− | log(p
2 + (1− p)2|
2
,
then the distribution will be G-almost surely absolutely continuous with a contin-
uous density.
To sum up, we find that, in this model, the long term concentration will vary
erratically in most cases of interest, and in particular for both p large and small.
Nonetheless, for moderate values of p (for instance for p = 1
2
), and µ large enough
(larger than 0.72 in the case p = 1
2
), one may find distributions of Z ensuring that
the concentration will be smooth.
Note finally that one could consider a (perhaps less natural) variant of the
above model: instead of having a fixed law G for the random dose perturbation,
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one may allow G to depend on the time discretization. Denote Gp this new family
of laws. One could imagine that, in the continuous limit, the randomness on doses
vanishes, i.e. Gp tends to a Dirac at Z = 1 when p tends to 0. In this case, and
depending on the speed of convergence of Gp, one may use again Theorem 2.1
of [13] to prove that, conditionally on Gp, the family of discrete distributions FZp
will be, under some assumptions, absolutely continuous.
8 Appendix
8.1 Proof of Proposition 5
Fix x > 0 and ε > 0. Recall the inversion formula for characteristic functions:
F (x+ ε)− F (x) = 1
2pi
lim
T→∞
∫ T
−T
e−iθ(x+ε) − e−iθx
−iθ ϕ(θ)dθ.
Now,
∣∣∣∣∫ 1−1 e
−iθ(x+ε) − e−iθx
−iθ ϕ(θ)dθ
∣∣∣∣ 6 ∫ 1−1 |e
−iθε − 1|
θ
dθ
6 2ε.
and:
∫ T
1
e−iθ(x+ε) − e−iθx
−iθ ϕ(θ)dθ =
∫ T
1
e−iθ(x+ε) − e−iθx
−iθ θ
−µdθ +
∫ T
1
e−iθ(x+ε) − e−iθx
−iθ O(θ
−µ−1)dθ.
But:
∣∣∣∣∫ T
1
e−iθ(x+ε) − e−iθx
−iθ O(θ
−µ−1)dθ
∣∣∣∣ 6 K ∫ T
1
|e−iθε − 1|
θµ+2
dθ
6 Kε
∫ T
1
1
θµ+1
dθ
6 Kε(1− 1
T µ
),
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so that
lim
T→∞
∣∣∣∣∫ T
1
e−iθ(x+ε) − e−iθx
−iθ O(θ
−µ−1)dθ
∣∣∣∣ 6 Kε.
Set now ε = ε′x then u = θx to get:
∫ T
1
e−iθ(x+ε) − e−iθx
−iθ θ
−µdθ =
∫ T
1
e−iθx(1+ε
′) − e−iθx
−iθµ+1 dθ
= ixµ
∫ xT
x
e−iu
e−iuε
′ − 1
uµ+1
du.
Integrating by parts, one gets∫ xT
x
e−iu
e−iuε
′ − 1
uµ+1
du =
[
ie−iu
e−iuε
′ − 1
uµ+1
]xT
x
−i
∫ xT
x
e−iu
(−iε′e−iuε′
uµ+1
− (µ+ 1)(e
−iuε′ − 1)
uµ+2
)
du.
We have: [
ie−iu
e−iuε
′ − 1
uµ+1
]∞
x
= ie−ix
e−ixε
′ − 1
xµ+1
= O(ε)
when ε→ 0.
Since the integral
∫∞
x
e−iu e
−iuε′
uµ+1
du is convergent, the term
∫∞
x
e−iu−iε
′e−iuε
′
uµ+1
du
is also O(ε). Finally, the term
∫∞
x
e−iu (µ+1)(e
−iuε′−1)
uµ+2
du is dealt with as above to
show that it is again O(ε).
8.2 Proof of Proposition 6
Thanks to our assumption on ν, (23) yields:
ϕrdt (θ) = exp
{
λ
∫ t
0
∫
A
[
exp(iθ
D
Vd
ue−k(t−x))− 1
]
ν(du)dx
}
= exp
{
λ
∫
A
∫ t
0
[
exp(iθ
D
Vd
ue−k(t−x))− 1
]
dxν(du)
}
.
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Setting y = θ D
Vd
ue−k(t−x), we get:
ϕrdt (θ) = exp
{∫
A
µ
∫ θ D
Vd
u
θ D
Vd
ue−kt
eiy − 1
y
dyν(du)
}
.
Letting t→∞,
ϕrd(θ) = exp
{∫
A
µ
∫ θ D
Vd
u
0
eiy − 1
y
dyν(du)
}
.
From the proof of proposition 4, we know that, when θ tends to infinity,
µ
∫ θ D
Vd
u
0
eiy − 1
y
dy ∼ K − µ(log(θ) + log(u))
for a certain constantK, with in addition µ
∫ θ D
Vd
u
0
eiy−1
y
dy−K+µ(log(θ)+log(u))
tending to 0. Thus, using the assumption on the logarithmic moment of ν,∫
A
µ
∫ θ D
Vd
u
0
eiy − 1
y
dyν(du) ∼ K − µ log(θ)− µ
∫
A
log(u)ν(du)
and one finishes up the proof with the help of a dominated convergence argument
to show that the difference between the right-hand side and the left-hand side in
the equivalent above indeed tends to 0 when θ tends to infinity.
8.3 Proof of Proposition 7
We shall prove Proposition 7 by showing that the characteristic function ϕp of Sp
tends pointwise to the characteristic function ϕ of C.
We first collect two technical lemmas that will be needed in the sequel.
Lemma 12. Let z ∈ C be such that |z| 6 1/2. Then Log (1 + z) = z + r(z) with
|r(z)| 6 |z|2, where Log denotes the principal value of the logarithm.
Proof.
We integrate dζ
ζ
over the segment [1, 1 + z], parametrized by ζ = 1 + zt :
Log (1 + z) =
∫ 1+z
1
dζ
ζ
=
∫ 1
0
z
1 + tz
dt.
48
Thus:
r(z) = Log (1 + z)− z =
∫ 1
0
z
1 + tz
dt−
∫ 1
0
z dt = −
∫ 1
0
tz2
1 + tz
If |z| 6 1/2, then |1 + tz| > 1/2 and
|r(z)| 6
∫ 1
0
∣∣∣∣ tz21 + tz
∣∣∣∣ dt 6 2|z|2 ∫ 1
0
t dt = |z|2
For any function f defined on R+, and for all natural numbers n, k > 1, let
S(f, n, k) denote the Riemann sum of f over [0, k] with step 1/n :
S(f, n, k) =
1
n
nk∑
j=1
f
(
j
n
)
Provided f is sufficiently regular and integrable, one has lim
n→∞
S(f, n, k) =∫ k
0
f(t) dt. By dominated convergence, lim
k→∞
lim
n→∞
S(f, n, k) =
∫ ∞
0
f(t) dt. The
next lemma gives a sufficient condition on an increasing sequence of integers
(kn)n∈N ensuring that lim
n→∞
S(f, n, kn) =
∫ ∞
0
f(t) dt.
Lemma 13. Let f be defined on R+. Assume f is Lipschitzian and integrable. If
kn = o(n), n → ∞, then S(f, n, kn) converges to the integral of f when n tends
to infinity.
Proof.
Write:
S(f, n, kn) =
∫ ∞
0
nkn∑
j=1
f
(
j
n
)
1 [(j−1)/n,j/n[(t) dt.
One has:
S(f, n, kn)−
∫ ∞
0
f(t) dt =
nkn∑
j=1
∫ j/n
(j−1)/n
(
f
(
j
n
)
− f(t)
)
dt−
∫ ∞
kn
f(t) dt.
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The last term in the right hand side above tends to 0 by dominated conver-
gence. The absolute value of each of the nkn terms in the sum is bounded by
1
n
ω
(
1
n
)
, where ω is the modulus of continuity of f . This implies that the abso-
lute value of the sum is not larger than knω
(
1
n
)
6 Ckn/n, which tends to 0 by
assumption when n tends to infinity.
Remark. The proof above shows that the conclusion of the lemma holds for kn =
o(1/ω(1/n)).
Proof of proposition 7.
Recall that ϕp denotes the characteristic function of Sp, and let ϕYj denote the
one of Yj . One has:
ϕp(θ) =
∞∏
j=1
ϕYj(θ) =
∞∏
j=1
(
1 + p
(
eia
jθ − 1
))
.
For p small enough, all the 1 + p
(
eia
jθ − 1
)
lie in the half-plane Re z > 0,
and we may permute the logarithm and the product. In addition, again for p small
enough, |p
(
eia
jθ − 1
)
| < 1
2
so that we may apply Lemma 12 to get Logϕp(θ) =
∞∑
j=1
Log
(
1 + p(eia
jθ − 1)
)
=
∞∑
j=1
[
p(eia
jθ − 1) + r
(
p(eia
jθ − 1)
)]
.
Denote ψp(θ) = p
∞∑
j=1
eia
jθ − 1 and Rp(θ) =
∞∑
j=1
r
(
p(eia
jθ − 1)
)
.
We first obtain an upper bound for the remainder term Rp using the fact that
|r(z)| 6 |z|2 : |Rp(θ)| 6
∞∑
j=1
p2|eiajθ−1|2. Since eiajθ−1 = 2ieiajθ/2 sin(ajθ/2),
one has |eiajθ − 1|2 = 4 sin2(ajθ/2) 6 a2jθ2 and
|Rp(θ)| 6 p2θ2
∞∑
j=1
a2j =
p2θ2a2
1− a2 .
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Apply the inequality 1 − e−u > ue−u, valid for all u > 0, with u = 2p/µ to
get 1− a2 = 1− e−2p/µ > 2 p
µ
e−2p/µ = 2 p
µ
a2. Finally,
|Rp(θ)| 6 µpθ
2
2
,
which shows that lim
p→0
Rp(θ) = 0 uniformly on all compact sets.
Let us now deal with ψp. Write p = pn = c/n and thus a = an = e−c/µn,
where c ∈ (0, 1/2) is a constant. Denote kn = b
√
nc, A = An = nkn and define:
ψp(θ) =: ψ
1
p(θ) + ψ
2
p(θ) where
ψ1p(θ) = p
A∑
j=1
eia
jθ − 1,
ψ2p(θ) = p
∞∑
j=A+1
eia
jθ − 1.
Consider first ψ2p:
∣∣ψ2p(θ)∣∣ 6 p ∞∑
j=A+1
|θ|2aj = 2p|θ|a
A+1
1− a 6
2pµ|θ|aA+1
pa
= 2µ|θ|aA.
Since a = e−c/µn and A = n
√
n(1 + εn):
aA = e−c
√
n(1+εn)/µ 6 e−2c
√
n/µ,
as soon as n is sufficiently large to ensure that |εn| 6 1. As a consequence,
lim
n→∞
ψp2(θ) = 0 uniformly on all compact sets.
We will estimate the limit of ψ1p with the help of Lemma 13. Write:
ψ1p(θ) = p
A∑
j=1
eia
jθ − 1 = c
n
nkn∑
j=1
eiθe
−cj/µn − 1.
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This is equal to cS(f, n, kn) with f(t) = eiθe
−ct/µ−1. This function is continuous
on R+. Furthermore, since:
|f(t)| 6 2 sin e−ct/µ|θ| 6 2e−ct/µ|θ|,
and c/µ > 0, f is integrable. Finally, it is differentiable and one computes:
f ′(t) = −i c
µ
θe−ct/µeiθe
−ct/µ
,
thus
|f ′(t)| = c
µ
|θ|e−ct/µ 6 c
µ
|θ| <∞.
This shows that f is a Lipschitz function. Noting that kn = o(n), we may apply
Lemma 13 to obtain that S(f, n, kn) converges to the integral of f .
Gathering our results, we get:
lim
n→∞
ϕpn(θ) = exp
(
c
∫ ∞
0
(
eiθe
−ct/µ − 1
)
dt
)
= exp
(∫ ∞
0
(
eiθe
−v/µ − 1
)
dv
)
= exp
(
µ
∫ θ
0
eiu − 1
u
du
)
.
8.4 Proof of Proposition 10
Consider a generalized Bernoulli convolution of the form S =
∑∞
k=1 bkXk, where
(Xk) are Bernoulli random variables as above and (bk) is a sequence of positive
real numbers such that
∑∞
k=1 bk <∞. Then [1]:
• If, for all k, bk 6
∑∞
j=k+1 bj , the support of S is a closed interval.
• If for all large enough k, bk >
∑∞
j=k+1 bj , the support of S is a nowhere
dense set.
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• If for all large enough k, bk >
∑∞
j=k+1 bj , then S has a singular density and
the Hausdorf dimension of its support is limn→∞n
− log(2)
log(
∑∞
j=n+1 bj)
.
We apply these results with bk = akDk. Then, for all realizations of the (Dj)j ,
we have that bk 6 akdM and
∑∞
j=k+1 bj > dm
∑∞
j=k+1 a
j = dm
ak+1
1−a . A sufficient
condition for bk 6
∑∞
j=k+1 bj is thus that a > dMdm+dM . The other case follows in a
similar way. Note that:
dm
an+1
1− a 6
∞∑
j=n+1
bj 6 dM
an+1
1− a,
which entails the formula above for the Hausdorf dimension.
8.5 Proof of Proposition 11
Verifying the expression of the mean is straightforward (recall that E(Z) = 1).
For the variance, note that:
(Srerdp )
2 =
(
D
Vd
)2 [ ∞∑
j=0
(
j−1∏
n=0
Z2n
)
a2jD2jX
2
j + 2
∑
j<k
(
j−1∏
n=0
Zn
)(
k−1∏
n=0
Zn
)
aj+kDjDkXjXk
]
.
Now, for j < k,
E
[(
j−1∏
n=0
Z2n
)]
= E(Z2)j,
E
[(
j−1∏
n=0
Zn
)(
k−1∏
n=0
Zn
)]
= E
[(
j−1∏
n=0
Z2n
)(
k−1∏
n=j
Zn
)]
= E(Z2)j,
and thus
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E
[
(Srerdp )
2
]
=
(
D
Vd
)2 [ ∞∑
j=0
E(Z2)ja2jE(D21)p+ 2
∑
j<k
E(Z2)jaj+kp2
]
=
(
D
Vd
)2
p
[ ∞∑
j=0
E(Z2)jaj
(
ajE(D21) + 2p
∞∑
k=j+1
ak
)]
=
(
D
Vd
)2
p
[ ∞∑
j=0
E(Z2)jaj
(
ajE(D21) + 2p
aj+1
1− a
)]
=
(
D
Vd
)2
p
[
E(D21)
∞∑
j=0
E(Z2)ja2j + 2
pa
1− a
∞∑
j=0
E(Z2)ja2j
]
=
(
D
Vd
)2
p
1− a2E(Z2)
[
E(D21) + 2
pa
1− a
]
.
Note that the series
∑∞
j=0 E(Z2)ja2j does indeed converge, since Z is sup-
ported on (0, 1/a).
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